Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Birgit Lorenz, EURETINA 2021: Retinopathy of Prematurity – Clinical Features and treatment

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 14th 2021

It was a pleasure to speak with Birgit Lorenz (Justus-Lieibig-University Giessen, Hesse, Germany) about retinopathy of prematurity, its clinical features and treatment, and what imaging studies have taught us about the development of macular development arrest.

Questions

  1. Could you tell us a little about retinopathy of prematurity, its clinical features and treatment? (00:31)
  1. What have imaging studies taught us about the development of macular development arrest? (03:44)

Speaker Disclosure: Birgit Lorenz has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of EURETINA 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup